⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639655 | 0.70 | MEN1 (0.32) | — | |
| SCHEMBL19639614 | 0.62 | CHRNB2 (0.32) | — | |
| SCHEMBL11076670 | 0.61 | GRIN2D (0.52) | — | |
| SCHEMBL1695341 | 0.59 | — | — | |
| SCHEMBL3141645 | 0.58 | — | — | |
| SCHEMBL15510989 | 0.58 | — | — | |
| SCHEMBL21713783 | 0.57 | USP2 (0.33) | — | |
| SCHEMBL3150869 | 0.57 | — | — | |
| SCHEMBL22341286 | 0.57 | — | — | |
| SCHEMBL22532544 | 0.57 | CYP2C19 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464275-B1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-23 | — | — | US | disclosed |
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2017-11-30 | — | — | US | disclosed |